81/100 A · Elevated risk
No major risk flags in public sources TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.

✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)

CELLECTIS

Active Public limited company (SA) Scientific research & development Active for 26 years

Public limited company (SA) · RC 428859052 · Active since 2000

A

Overview

CELLECTIS is a public limited company (sa) registered in France, since 2000. The company operates in the scientific research & development sector. With reported revenue of 30.3M EUR in 2024. Its TraceComp score of 81 (A) indicates solid fundamentals and low apparent risk. With 26 years of operations, the company has an established track record in its market.

Company Information

Registration Number
428859052
Legal Form
Public limited company (SA)
Registered
2000-01-01

Financial Profile

Latest filed accounts: FY 2024

Revenue (2024) 30,281,445 EUR
Net Income -58,219,507 EUR
Total Assets 385,680,523 EUR
Altman Z 0.49 distress

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

14 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
ANDRE Choulika Deputy chief executive (directeur général délégué) Current
+ 13 more in the full report

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Patent Portfolio

Active patent holder. 97 patents · 96 active · 97 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Revenue up 2222% year-on-year
  • Net loss reported in FY 2024
  • Altman Z-Score in the distress zone — elevated insolvency risk on the model

Data Sources & Freshness

Data sourced from: bulk register.